This clinical quality registry aims to improve myeloma outcomes by providing an evidence base for the best strategies to diagnose, treat and support people with myeloma and related diseases.
Patients accrued
Patients with multiple myeloma
Number of approved sites
M1000 Biobank participants
An MRDR paper on the development and validation of a discrete-event simulation model of MM disease outcomes has now been published!
Read moreAn MRDR paper investigating variation in immunoglobulin use and survival in myeloma has now been published!
Read moreThe MRDR reaches another milestone of recruiting more than 7,000 patients!
Read moreThe MRDR supports Rare Disease Day 2024.
Read more
